The Innovation
The Innovation Journals: Serving Global Researcher
Date: 07 AUG 2024 (Wednesday)
Time: 16:00-17:00 (HKT)
Venue: Rm 10.13, Department of Geography, 10F, The Jockey Club Tower, Centennial Campus, HKU
Host: Professor Hongsheng ZHANG
Abstract:
The Innovation was launched in 2020 and has undergone rapid growth to become a rising star journal, which is a new broad-scope, open-access journal publishing basic and applied research that has an impact on the benefit of society. The Editorial Board consists of 196 members from 21 countries, whose research interests span all disciplines of science. The Innovation is designated to promote scientific translation by publishing the most significant and cutting-edge research papers and high-quality reviews, perspectives, commentaries, editorials, translational patents and news. Currently, The Innovation has been indexed by ESCI, DAOJ, ADS, Scopus, El, CAS Journal Ranking (Q1). To maximize visibility, we use a lot of social media platforms, including We Chat, Twitter, Facebook, Insta-gram, Channels, Tik Tok, Research Gate, Linked In, National Media (TV, newspapers) from the USA, China, and Australia to report your findings. All the published articles will be sent to 5,000-40,000 experts worldwide by email campaign. Noteworthy cases, such as one published in Volume 3 Issue 1, garnered over 1 million views within 4 hours of being reported by Xinhua Net. Another case, "Homo longi" (Dragon Man), amassed over 200 million views worldwide within 10 days. The Innovation achieved first Impact Factor of 33.1 as accredited by Clarivate in 2023. We anticipate maintaining this high standard in 2024. Furthermore, on June 25-28 2023, we proudly introduced four sister journals: The Innovation Life, The Innovation Geoscience, The Innovation Materials, The Innovation Medicine. On February 26th, 2024, we launched the fifth sister journal, The Innovation Energy. Each of these journals upholds the same rigorous standards as The Innovation. So far, the authors are from 64 countries and the papers had been cited by authors from 139 countries.
Ke CHEN
Exective Director, The Innovation
Ke Chen was a medical doctor and graduated from Peking University. Then, he worked at Beijing Institute of Genomics, Chinese Academy of Sciences (CAS) since 2009. In 2017, he was awarded the title of "Excellent Member" of the Youth Innovation Promotion Association of CAS. As a visiting scholar, he visited MD Anderson Cancer Center in the United States from 2018 to 2019. Dr. Chen is one of the founders of the multidiscipline journal, The Innovation. He mainly engaged in oncology-related research; hosted 2 National Natural Science Foundation of China projects and published 15 SCI-paper, including Cell Research, Cancer Cell, Emerging Infectious Diseases, etc.
Comments